| Similar Articles |
|---|
 |
Salon.com
June 9, 2001
Scott Rosenberg |
More lights go out on the Web The apparent demise of pioneering sites Feed and Suck leaves the online world an emptier, duller place...   |
The Motley Fool
July 14, 2008
Brian Orelli |
Foolish Forecast: J&J Trudges Along In advance of earnings analysts wonder if Johnson & Johnson is a recovery story waiting to happen, or still stuck in a rut? |
The Motley Fool
May 26, 2010
Brian Orelli |
Is Johnson & Johnson a Buy? Let's see what it says to Congress first on safety issues. |
The Motley Fool
August 24, 2009
Brian Orelli |
J&J Would Rather Not Say Drug delayed, reason unknown. Should shareholders be worried? It's hard to tell. |
Delicious Living
February 2005
Jean Weiss |
The Plastics Conundrum How does using plastic really affect us? Who knows. |
| Knowledge@Wharton |
The Bob Johnson Factor: How the BET Founder Is Building an Empire Entrepreneurs with good ideas and the right timing can find capital to finance their business if they build strong support networks, according to Robert L. Johnson, founder and chief executive of Black Entertainment Television. |
The Motley Fool
December 1, 2010
Brian Orelli |
We're Still Buying. Probably. Despite manufacturing problems, Johnson &Johnson continues with its purchase of Crucell. |
The Motley Fool
July 12, 2010
Brian Orelli |
Johnson & Johnson MENDs a Hole Another neurovascular device maker, Micrus Endovascular, gets snatched up. |
The Motley Fool
November 26, 2010
Brian Orelli |
Get It Together, Johnson & Johnson Another day, another recall. |
The Motley Fool
September 14, 2007
Brian Orelli |
J&J's Expensive RNA Purchase Johnson & Johnson sets up a collaboration with Isis Pharmaceuticals to develop compounds to treat diabetes. Investors take note. |
The Motley Fool
February 22, 2010
Brian Orelli |
So Long, See You in Arbitration After another rejection, Johnson & Johnson and Basilea call it quits. |
Wired
March 2001
Chip Bayers |
Crash Course At 23, Matt Johnson had it all: the business plan, the VC money, and grand designs to dominate the untapped college market. Then the BigWords boy wonder got a harsh lesson in dotcom reality... |
The Motley Fool
April 29, 2011
David Williamson |
Johnson & Johnson's Traumatic Purchase Johnson & Johnson agrees to purchase trauma and spine specialist Synthes. |
The Motley Fool
June 28, 2011
Eric Bleeker |
Johnson & Johnson Is Looking Abroad for Growth Where's Johnson & Johnson generating its sales? |
The Motley Fool
July 31, 2007
Nathan Parmelee |
Break Out the Band-Aids at J&J Johnson & Johnson is making some deep cuts to change its cost structure. Shareholders haven't had much to cheer about lately here, but the potential benefits from this move could help cure some of the current softness in the business. |
The Motley Fool
July 12, 2011
Todd Wenning |
What Does Johnson & Johnson Do With Its Free Cash? Johnson & Johnson appears to be making fair use of its free cash flow, and its well-covered dividend may be attractive to income-focused investors. |
The Motley Fool
December 1, 2008
Brian Orelli |
Johnson & Johnson Firms Things Up The health-care giant acquires breast-implant maker Mentor. |
The Motley Fool
August 24, 2010
Brian Orelli |
One Day, the J&J Recalls Will End Just not today. Johnson & Johnson's consumer health segment gets more than half of its sales from outside the U.S., so tainting its image outside the U.S. could be costly as well. |
The Motley Fool
August 14, 2007
Brian Orelli |
A No-Win Situation Johnson & Johnson is suing the beloved American Red Cross for trademark infringement. Johnson & Johnson just needs to walk a fine line between having its brand eroded by the Red Cross and having its brand eroded by a public relations nightmare. |
The Motley Fool
January 18, 2012 |
What Johnson & Johnson Does With Its Cash Over the last five years, Johnson & Johnson shares returned 14%, which drops to -3% without dividends -- not a bad boost to top off otherwise lowly share performance. |
The Motley Fool
October 12, 2004
Alyce Lomax |
Take It Away, J&J Should investors sweat a coming slowdown in growth for pharmaceutical and consumer products giant Johnson & Johnson? |
The Motley Fool
July 9, 2010
Brian Orelli |
Hey, Johnson & Johnson: Eight Is Enough If Johnson & Johnson can't overcome the negative image from recalls quickly, consumers will head to competing brand-name drugs or just grab generic versions of Johnson & Johnson's products. |
The Motley Fool
August 27, 2010
Brian Orelli |
A Recall a Week, That's All We Ask For Johnson & Johnson, apparently that's too much. |
Bank Systems & Technology
March 30, 2004
Cynthia Ramsaran |
MasterCard Cashes In On Recurring Payments Merchants follow the card company's lead to improve their bottom lines by cutting processing costs and increasing customer retention with automatic payments. |
The Motley Fool
May 26, 2009
Brian Orelli |
Buy Now! It Might Get Bought! Clinical trial results and FDA approvals ultimately drive any increase in drugmakers' value. That's what pharmaceutical investors should focus on. The potential for an acquisition should be nothing more than icing on the cake. |
Salon.com
April 24, 2001
Jake Tapper |
Virtually NORML Gov. Gary Johnson comes to Washington hoping to find converts to his anti-drug war crusade. He leaves one frustrated man... |
IEEE Spectrum
May 2006
Lauren Aaronson |
Parallel Processor How IBM engineer Sandra Johnson contributes to her field, her business, and the community. |
The Motley Fool
June 4, 2010
Brian Orelli |
Out With Drugs, in With Medical Devices Johnson & Johnson's movement in medical devices and diagnostics is headed in the right direction, but whether Johnson & Johnson is a buy depends a lot on how it handles its current drug problem. Unfortunately investors can't have one without the other. |
The Motley Fool
May 28, 2010
Brian Orelli |
How Much Is This Going to Cost J&J? Investors need an answer from Johnson & Johnson about low-quality drugs that were recalled. Is the problem systemic, and if so, how much will it cost the company to fix the problem? |
The Motley Fool
August 19, 2010
Brian Orelli |
Buffett Is Buying J&J. Should You? It depends on your time horizon. |
The Motley Fool
May 8, 2009
Selena Maranjian |
The Mind-Boggling Power of Dividends Who knew they drove so much value growth? |
The Motley Fool
June 25, 2010
Brian Orelli |
The Joys of Being Large and Diversified Johnson & Johnson's plant closure is a rounding error. |
The Motley Fool
January 26, 2010
Brian Orelli |
Is the Best of Johnson & Johnson Behind It? Johnson & Johnson announces that its sales fell for the first time in 76 years. |
The Motley Fool
September 30, 2009
Brian Orelli |
Boston Scientific Pays Up And Johnson & Johnson reaps the rewards. |
The Motley Fool
September 25, 2009
Brian Orelli |
Oh, No! Another Tylenol Recall? Take a deep breath. Everything will be OK. |
The Motley Fool
October 19, 2011
Brian Orelli |
Not the Best Quarter, but... There's little reason to worry about Johnson & Johnson. |
The Motley Fool
September 15, 2009
Brian Orelli |
What's $115 Million Between Friends? Elan has to fix the mess it had gotten itself into with its multiple sclerosis drug Tysabri. |
The Motley Fool
January 23, 2008
Brian Orelli |
A Dose of Stability From J&J Top-line growth looked great at Johnson & Johnson -- more than 16% year over year -- but when you dove a little further into the earnings, growth wasn't quite that stellar. |
The Motley Fool
February 23, 2009
Brian Orelli |
The DOJ v. Johnson & Johnson The U.S. Department of Justice is joining a lawsuit against the health care giant over the company's marketing of heart failure drug Natrecor. |
Inc.
April 2004
Alison Stein Wellner |
Case Study Colin Johnson had a bold plan to transform his consulting firm. But when things went awry, sticking to his guns meant risking everything. |
HBS Working Knowledge
May 15, 2006
Diane Coutu |
LBJ's Deliberate March for Power When a leader gets enough power -- when he's president of the United States or CEO of a major corporation -- then we can see what he wanted to accomplish all along. Here, a Harvard expert discusses Lyndon B. Johnson's strategy for getting close to powerful people. |
The Motley Fool
November 28, 2008
Brian Orelli |
The FDA's Killing Bug Killers Unfortunately for Johnson & Johnson and Swiss drugmaker Basilea Pharmaceutica, the FDA appears a little reluctant to take some of the data for the drugmakers' antibiotic ceftobiprole at face value. |
Reason
July 2002
John J. Pitney Jr. |
New Criticism A history of the 1990s, Haynes Johnson's The Best of Times: America in the Clinton Years, misses the good old days -- and the truth. |
Fast Company
Chris Gayomali |
Are Selfies Fueling A Plastic Surgery Boom? The idea that selfies are powering a plastic surgery boom is certainly a convenient narrative, ripe for rage-tweeting. It is also not an entirely false narrative. |
The Motley Fool
November 27, 2009
Brian Orelli |
A Mostly Meaningless FDA Approval After an accelerated approval, the positive effects of a full approval are minimal for Johnson & Johnson's drug, Intelence. |
The Motley Fool
February 24, 2009
Brian Orelli |
Pfizer: Diversified Dreams, Dubious Decisions Pfizer's CEO Jeffrey Kindler said he wants to make his company more like Johnson & Johnson and Abbott Labs, which aren't dependent on one product for success. |
BusinessWeek
June 6, 2005
Spencer E. Ante |
Thriving On "Trash" Steven Johnson's new book, Everything Bad is Good for You, explains how today's popular culture is actually making us smarter. But it may overstate its case. |
The Motley Fool
February 28, 2011
Brian Orelli |
Johnson & Johnson Parties Like It's 1982 The big pharma announced that it was recalling 667,632 packages of Sudafed tablets because the instructions contained a typo. |
The Motley Fool
July 19, 2011
Brian Orelli |
J&J: Better, but Not Best A decent-looking quarter, but a turnaround could still take awhile. |
The Motley Fool
January 15, 2010
Brian Orelli |
The Odor Lingers at Johnson & Johnson The company has to recall products because of a smelly problem. |
